Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: A double-blind randomized controlled trial

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 33, Issue 2, 2013, Pages 189-194

  Pan, Xiao Li ^a   Zhao, Li ^a   Li, Liang ^a   Li, Ai Hua ^a   Ye, Jin ^a   Yang, Ling ^a   Xu, Ke Shu ^a   Hou, Xiao Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Liver cirrhosis; Serum markers; Tauroursodeoxycholic acid; Ursodeoxycholic acid

Indexed keywords

CHOLAGOGUE; TAUROCHENODEOXYCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CHOLAGOGUES AND CHOLERETICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TAUROCHENODEOXYCHOLIC ACID; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84902459143     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-013-1095-x     Document Type: Article

References (24)

1. Kuiper EM, Hansen BE, Lesterhuis W, et al. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-Advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol, 2011, 35(1):29-33
2. Wang X, Shen S, Li N, et al. Effect of ursodeoxycholi acid on liver cirrhosis with hepatitis B. Zhong Nan Da Xue Xue Bao Yi Xue Ban (Chinese), 2010, 35(2):171-175
3. Fischer S, Muller I, Zundt BZ, et al. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur J Gastroenterol Hepatol, 2004, 16(3):305-311
4. Rodriques CM, Kren BT, Steer CJ, et al. Tauroursodeoxycholate increases rat liver ursodeoxycholate levels and limits lithocholate formation better than ursodeoxycholate. Gastroenterology, 1995, 109(2):564-572
5. Fickert P, Fuchsbichler A, Marschall HU, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol, 2006, 168(2):410-422
6. Invernizzi P, Setchell KDR, Crosignani A, et al. Differences in the metabolism and disposition of ursodeoxycholic acid and its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology, 1999, 29(2): 320-327
7. Crosignani A, Battezzati PM, Setchell KD, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci, 1996, 41(4):809-815
8. Setchell KD, Rodrigues CM, Podda M, et al. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut, 1996, 38(3): 439-446
9. Boatright JH, Nickerson JM, Moring AG, et al. Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor, 2009, 2(3):149-159
10. Chinese Society of Infectious Diseases and Parasitoloy and Chinese Society of Hepatology of Chinese Medical Association. The programme of prevention and cure for viral hepatitis. Zhonggua Gan Zang Bing Za Zhi (Chinese), 2000, 8(6):324-329
11. Wang TL, Liu X, Zhou YP. Inflammatory activity of chronic hepatitis and fibrosis scoring program. Zhong Hua Gan Zang Bing Za Zhi (Chinese), 1998, 6(4):195-197
12. Caglieris S, Giannini E, Dardano G, et al. Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. Hepatogastroenterology, 2000, 47(34):1045-1047
13. Úriz M, Sáez E, Prieto J, et al. Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLos One, 2011, 6(12):e28717
14. Ben Mosbah I, Alfany-Fernandez I, Martel C, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis, 2010, 8(1):e52
15. Rodrigues CM, Sola S, Sharpe JC, et al. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry, 2003, 42(10):3070-3080
16. Schoemaker MH, Conde de la Rosa L, Buist-HomanM, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology, 2004, 39(6):1563-1573
17. Terasaki S, Nakanuma Y, Oqino H, et al. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol, 1991, 86(9):1194-1199
18. Liu L, Sakaquchi T, Cui X, et al. Liver regeneration enhanced by orally administered ursodesoxycholic acid is mediated by immunosuppression in partially hepatic tomized rats. Am J Clin Med, 2002, 30(1):119-126
19. Kuiper EM, Hansen BE, Lesterhuis W, et al. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-Advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol, 2011, 35(1):29-33
20. Dan W, Ling Y, Jinming H, et al. Tauroursodeoxycholic acid inhibits carbon tetrachloride-induced liver fibrosis in rats. Shi Jie Hua Ren Xiao Hua Za Zhi (Chinese), 2010, 18(19):1979-1984
21. Colell A, Coll O, Garcia-Ruiz C, et al. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology, 2001, 34(5):964-971
22. Zhang LX, Liang TJ, Tan YR, et al. Protective effects of ursodeoxycholic acid against immune-mediated liver fibrosis in rats. Hepatogastroenterology, 2010, 57(102-103): 1196-1202
23. Voumvouraki A, Koulentaki M, Notas G, et al. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med, 2011, 22(1):77-83
24. Larghi A, Crosignani A, Battezzati PM, et al. Ursodeoxycholic and tauroursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther, 1997, 11(2):409-414